Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

Last updated: August 15, 2023
Sponsor: Handok Inc.
Overall Status: Completed

Phase

3

Condition

Vascular Diseases

High Blood Pressure (Hypertension - Pediatric)

Diabetes And Hypertension

Treatment

Irbesartan/Amlodipine high

Irbesartan/Amlodipine low

Irbesartan

Clinical Study ID

NCT05476354
HD-AI-301
  • Ages > 19
  • All Genders

Study Summary

The purpose of this study is to evaluate efficacy and safety of Irbesartan and Amlodipine combined therapy in patients with essential hypertension inadequately controlled on Irbesartan monotherapy

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients who are 19 years or older on screening
  • Signed informed consent
  • Patients with Essential Hypertension
  • Other inclusion applied

Exclusion

Exclusion Criteria:

  • Orthostatic hypotension
  • Other exclusion applied

Study Design

Total Participants: 271
Treatment Group(s): 3
Primary Treatment: Irbesartan/Amlodipine high
Phase: 3
Study Start date:
July 05, 2022
Estimated Completion Date:
June 13, 2023

Connect with a study center

  • Severance Hospital

    Seoul, 03722
    Korea, Republic of

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.